FDA Panel Unanimously Endorses New RSV Antibody Drug for Infants

A sheet of outside advisers to the U.S. Food and Drug Administration (FDA) voted successful favour of approving a preventative antibody attraction for respiratory syncytial microorganism (RSV) for in newborns and infants. The unanimous vote by 21 members of the FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) connected Thursday brings the monoclonal antibody, nirsevimab, person to last support by the FDA. All connected the advisory sheet ...